

Humira Biosimilar Coverage Overview

2025 Coverage Overview for Blue Advantage Members

Humira® (adalimumab) is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

Humira is preferred on all Blue Advantage (HMO) | Blue Advantage (PPO) formularies.* The following describes our 2025 coverage and basic information.

Prior Authorization Important Notes	<ul style="list-style-type: none"> Members with an approved authorization for Humira do not require a new prior authorization to switch to any other preferred adalimumab product listed in this guide. All new adalimumab prescriptions require a prior authorization request for clinical review. Approved prior authorizations for Humira will apply to all preferred adalimumab biosimilars.
--	---

2025 BLUE ADVANTAGE Preferred Humira Biosimilars

Product	Manufacturer	Concentration	Citrate Free	Interchangeable
Cyltezo®	Boehringer Ingelheim	Low High	✓ ✓	Yes Seeking
Yuflyma®	Celltrion	High	✓	Seeking

**This guide does not apply to Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. commercial plans.*

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross Blue Shield Association.

Humira Biosimilar Attributes

Concentration	A higher concentration means less injection volume. Adalimumab biosimilars are available in an original concentration (50 mg/ml) and/or a high concentration (100 mg/ml).
Citrate vs Citrate Free	Citrate free formulations help to reduce pain and burning during administration that is often reported by patients when administering formulations that contain citrate.
Interchangeability Status	Interchangeable biosimilars are able to be substituted for the reference product at the pharmacy without consulting the prescriber before filling.
Cost	A biosimilar is usually less expensive than the reference product and offers a more affordable, yet equally efficacious, treatment option.

Additional Education

What is a biosimilar?

A biosimilar is a biological product that is highly similar to an existing FDA-approved biological product, also known as the reference product. A biosimilar has no clinically meaningful differences in safety, efficacy, purity and potency from the reference product.

Facts about biologic products and prescribing

- » Biologic products are large and generally complex molecules that are produced from living organisms such as bacteria, yeast and animal cells.
- » Biosimilars have the same route of administration, strength, dosage, treatment benefits and potential side effects as the reference product.
- » Biosimilars may offer more affordable treatment options to patients.
- » Biosimilars may also be interchangeable. An interchangeable biosimilar is one that meets additional requirements and may be substituted for the reference product by a pharmacist without consulting the prescriber before filling. Louisiana law requires the patient's consent and the pharmacist notify the prescriber within 5 business days of the dispense date.

Have clinical questions?

Email pharmacybenefits@lablue.com

Blue Advantage from Blue Cross and Blue Shield of Louisiana is an HMO plan with a Medicare contract.
Blue Advantage from Blue Cross and Blue Shield of Louisiana is a PPO plan with a Medicare contract.
Enrollment in either Blue Advantage plan depends on contract renewal.